Drug Profile
Research programme: cancer immunotherapies - Avacta/OncoSec Medical
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Avacta; OncoSec Medical
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for research development in Cancer in United Kingdom (Parenteral)
- 12 Feb 2018 Avacta and OncoSec Medical enters into a research collaboration to develop immunotherapy combinations for cancer
- 12 Feb 2018 Early research in Cancer in United Kingdom (Parenteral)